Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Crafts Import Safety Bill, As Device Reps Prep For House Hearing

This article was originally published in The Gray Sheet

Executive Summary

Sen. Ted Kennedy, D-Mass., is crafting a bill to strengthen FDA's oversight of products manufactured overseas, including devices
Advertisement

Related Content

Device, Drug Import Safety Legislation Resurfaces
Device, Drug Import Safety Legislation Resurfaces
Compliant Device, Drug Importers Should Get Preference At Border – Industry
Post-Election Industry Outlook: New User Fees, More Aggressive FDA
Import Safety Tops FDA Device Center’s FY 2009 Priorities
Execs Could Go To Jail For False Info In FDA Submissions Under Senate Bill
Industry Opposes Idea Of New FDA Inspection Authority, Fee At House Hearing
Draft House Bill Seeks To Strengthen FDA’s Role In Device Import Safety
Draft House Bill Seeks To Strengthen FDA’s Role In Device Import Safety
OC FY 2005 Priorities: MDUFMA, Bioterror, Closing Out Enforcement Actions
Advertisement
UsernamePublicRestriction

Register

MT026114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel